Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection

HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
PEDIATRICS (Impact Factor: 5.3). 12/2005; 116(6):e846-54. DOI: 10.1542/peds.2005-0975
Source: PubMed

ABSTRACT Highly active antiretroviral therapy has altered the course of HIV infection among children, but new antiretroviral agents are needed for treatment-experienced children with drug-resistant virus. Tenofovir disoproxil fumarate (DF) is a promising agent for use in pediatric salvage therapy, because of its tolerability, efficacy, and resistance profile. We designed this study to provide preliminary pediatric safety and dosing information on tenofovir DF, while also providing potentially efficacious salvage therapy for heavily treatment-experienced, HIV-infected children.
Tenofovir DF, alone and in combination with optimized background antiretroviral regimens, was studied among 18 HIV-infected children (age range: 8.3-16.2 years) who had progressive disease with > or = 2 prior antiretroviral regimens, in a single-center, open-label trial. Tenofovir DF monotherapy for 6 days was followed by the addition of individualized antiretroviral regimens. Subjects were monitored with HIV RNA reverse transcription-polymerase chain reaction, flow cytometry, and routine laboratory studies; monitoring for bone toxicity included measurement of lumbar spine bone mineral density (BMD) with dual-energy x-ray absorptiometry. Subjects were monitored through 48 weeks.
Two subjects developed grade 3 elevated hepatic transaminase levels during monotherapy and were removed from the study. The remaining 16 subjects had a median of 4 antiretroviral agents (range: 3-5 agents) added to tenofovir DF. HIV plasma RNA levels decreased from a median pretreatment level of 5.4 log10 copies per mL (range: 4.1-5.9 log10 copies per mL) to 4.21 log10 copies per mL at week 48 (n = 15), with 6 subjects having < 400 copies per mL, including 4 with < 50 copies per mL. The overall median increases in CD4+ T cell counts were 58 cells per mm3 (range: -64 to 589 cells per mm3) at week 24 and 0 cells per mm3 (range: -274 to 768 cells per mm3) at week 48. The CD4+ cell responses among the virologic responders were high and sustained. The major toxicity attributed to tenofovir DF was a >6% decrease in BMD for 5 of 15 subjects evaluated at week 48, necessitating the discontinuation of tenofovir DF therapy for 2; all 5 subjects experienced >2 log10 copies per mL decreases in HIV plasma RNA levels.
Tenofovir DF-containing, individualized, highly active antiretroviral therapy regimens were well tolerated and effective among heavily treatment-experienced, HIV-infected children. Loss of BMD may limit tenofovir DF use among prepubertal patients.

Download full-text


Available from: John F Flaherty, Jan 07, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Virologic response to highly active antiretroviral therapy (HAART) treatment of HIV infection depends on viral sensitivity to antiretrovirals and excellent medication adherence. Adolescents with vertically acquired HIV may require complicated regimens because of significant treatment experience and often have poor medication adherence. A retrospective chart review identified five adolescents with vertically acquired HIV and plasma HIV viral load rebound or nonresponse on a stable HAART regimen followed by a period of directly observed therapy (DOT) in a clinic or hospital setting with serial viral load measurements. Four subjects had a virologic response (mean decline, 1.15 log10) after DOT. A response to HAART can be seen despite antiretrovirals resistance using DOT and treatment-experienced patients seemingly unresponsive to HAART may be nonadherent even with reassuring adherence measures. A period of clinic-monitored DOT may allow diagnosis of nonadherence, discussion of medication barriers, and avoidance of unnecessary medication changes.
    Journal of the Association of Nurses in AIDS Care 03/2008; 19(2):158-65. DOI:10.1016/j.jana.2007.08.003 · 1.23 Impact Factor
  • The Pediatric Infectious Disease Journal 01/2015; DOI:10.1097/INF.0000000000000650 · 3.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tenofovir (TFV) exposure is associated with antiretroviral efficacy and risk of kidney disease. There is evidence of high inter-individual variability of the pharmacokinetics of TFV. The effect of several clinical conditions on the pharmacokinetics of TFV has been observed and may partly explain its variability. We assessed factors influencing the pharmacokinetics of TFV in Thai patients.. Thirty participants (50% female) taking efavirenz- or ritonavir-boosted protease inhibitors based regimens were investigated. Intensive pharmacokinetic sampling was performed over 24 hours.. Multivariate geometric mean regression models adjusted for covariates with P≤0.2 in univariate analysis were developed. Median age was 41 years. Five participants (3 taking PI and 2 taking EFV) had mild renal dysfunction (eGFR60-90mL/min/1.73m2; range 72-89). TFV AUC0-24 was 23% (95%CI 1-49%; P = 0.04) higher in those taking PI vs EFV, 39% (95%CI 5 - 84%; p=0.02) higher in those with mild renal dysfunction and reduced by 16% (95%CI 5 - 26%; p = 0.008) with each 10kg body weight increase, after adjusting for sex and duration of TFV exposure. In PI-treated subjects TFV AUC0-24 increased by 3% (0.3 - 6%; p = 0.03) for each mg*h/L increase in RTV AUC0-24 after adjusting for sex, weight, mild renal impairment and proximal renal tubular dysfunction. Significantly higher TFV exposures were independently associated with PI regimens, mild renal impairment, lower body weight and increasing RTVAUC0-24. Clinicians should be aware of the effect of these factors on TFV exposure when this drug is prescribed.
    AIDS Research and Human Retroviruses 11/2014; 31(4). DOI:10.1089/AID.2014.0249 · 2.46 Impact Factor